Scenic Biotech BV announces $31m financingScenic Biotech BV will use an incoming $31m (€28) Series A financing to advance its pipeline of genetic modifiers, a new molecular entity in cancer and rare disease. more ➔ · & … more ➔
Kurma Partners closes growth fund at €16...French venture capital expert Kurma Partners has closed its Growth Opportunities Fund at €160m and targets a final closing at €250m. more ➔
mRNA for AfricaModerna will build its first mRNA production facility in Kenya, investing up to US$500m. more ➔
Epsilogen raise £30.75m in Series B finan...IgE cancer antibody specialist Epsilogen Ltd has closed a £30.75m round led by Novartis Venture Fund to advance Phase Ib studies with MOv18 IgE in platinum-resistant ovarian cancer. more ➔
Syndesi swallowed by AbbvieAbbVie has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie’s neuroscience portfolio. more ➔
Chinese Huadong snaps up Heidelberg Pharma...ADC manufacturer Heidelberg Pharma AG has negotiated a US$931m licensing and investment deal with China’s Huadong Medicine Co, Ltd.The German inventor of alpha-amanitin antibody conjugates (ATACs) will … more ➔
Meletios Therapeutics licences antiviral p...Paris-based Meletios Therapeutics SA has licenced know-how from the Institut Pasteur for the development of a new class of antivirals- more ➔
ECBF oversubscribed closing at €300mThe European Circular Bioeconomy Fund has announced its final closing at €300m, €50m above its target. more ➔
TargED Biopharmaceuticals BV raises €39m...TargED Biopharmaceuticals will use €39m from a Series A financing to bring its thrombolytic treatment to patients. more ➔
Finnish VTT spin-out Onego Bio Ltd raises...The cellular agriculture spin-off Onego Bio Ltd has been seeded with €10m to use its Trichoderma platform to establish an animal-free egg protein production. more ➔
